Modalidades de tratamiento locales y sistémicos de hepatocarcinoma
Local and systemic treatment modalities of hepatocarcinoma
Palabras clave:
carcinoma hepatocelular, quimioembolización, ablación, sorafenib
Resumen
El carcinoma hepatocelular (CHC) es una de las principales causas de muerte relacionada con el cáncer a nivel mundial. Existen terapias locales y sistémicas para el tratamiento del CHC. Un enfoque multidisciplinario es fundamental para el tratamiento exitoso del CHC. La clasificación por estadios de Barcelona es el mejor sistema para determinar el pronóstico de los pacientes y está vinculada a un algoritmo de tratamiento basado en la evidencia. El CHC en estadio temprano se maneja mejor con un tratamiento curativo, que incluye resección, ablación o trasplante. Los pacientes con enfermedad en estadio intermedio a menudo reciben tratamiento locorregional como la quimioembolización transarterial y la radioembolización. El tratamiento sistémico con sorafenib se reserva para pacientes con enfermedad avanzada.
Descargas
La descarga de datos todavía no está disponible.
Citas
Karadag Soylu N. Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint. J Gastrointest Cancer. 2020;51(4):1176-1186. doi: 10.1007/s12029-020-00499-5. PMID: 32844348.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. doi:10.1200/JCO.2008.20.7753 pmid:19224838.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604. doi:10.1038/s41575-019-0186-y pmid:31439937.
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi: 10.1136/bmj.m3544. PMID: 33106289.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma [correction in: J Hepatol 2019;70:817]. J Hepatol 2018;69:182-236. pmid:29628281.
Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci. 2019;20(6):1465. doi: 10.3390/ijms20061465. PMID: 30909504; PMCID: PMC6470895.
Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. doi:10.1155/2018/4756147 pmid:29974040.
O'Leary C, Mahler M, Soulen MC. Liver-directed therapy for hepatocellular carcinoma. Chin Clin Oncol. 2021;10(1):8. doi: 10.21037/cco-20-51. Epub 2020 May 30. PMID: 32527111.
Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World J Gastroenterol 2018;24:5331-7. doi:10.3748/wjg.v24.i47.5331 pmid:30598578
Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol 2019;29:654-62. doi:10.1007/s00330-018-5617-6 pmid:30043160.
Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018;3:317-25. doi:10.1016/S2468-1253(18)30029-3 pmid:29503247.
Llovet JM, Real MI, Montaña X, et al., Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. doi:10.1016/S0140-6736(02)08649-X pmid:12049862.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22. doi:10.1016/S1470-2045(11)70175-9 pmid:22047762.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7. PMID: 26765068.
Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26(4):516-22. doi: 10.1016/j.jvir.2014.12.020. Epub 2015 Feb 18. PMID: 25704226.
Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. doi:10.1111/liv.12314 pmid:24251922.
Kudo M, Matsui O, Izumi N, et al., Liver Cancer Study Group of Japan. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology2014;87(Suppl 1):22-31. doi:10.1159/000368142 pmid:25427730.
Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:25-9. doi: 10.2147/JHC.S50359. PMID: 27574589; PMCID: PMC4994804.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. doi: 10.1056/NEJMoa0708857. PMID: 18650514.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. PMID: 19095497.
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609-17. doi: 10.1111/ijcp.12352. Epub 2013 Nov 28. PMID: 24283303; PMCID: PMC4265239.
Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188391. doi: 10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10. PMID: 32659252.
Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959. doi: 10.1177/17562848211016959. PMID: 34104211; PMCID: PMC8165525.
Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs. 2020;80(12):1203-1210. doi: 10.1007/s40265-020-01361-5. PMID: 32671719; PMCID: PMC7395054.
Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs. 2020;80(3):315-322. doi: 10.1007/s40265-020-01263-6. PMID: 32034692.
Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22. PMID: 30304963.
Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993-3036. PMID: 33042631; PMCID: PMC7539784.
May P, Normand C, Cassel JB, Del Fabbro E, Fine RL, Menz R, Morrison CA, Penrod JD, Robinson C, Morrison RS. Economics of Palliative Care for Hospitalized Adults With Serious Illness: A Meta-analysis. JAMA Intern Med. 2018;178(6):820-829. doi: 10.1001/jamainternmed.2018.0750. PMID: 29710177; PMCID: PMC6145747.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. doi:10.1200/JCO.2008.20.7753 pmid:19224838.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604. doi:10.1038/s41575-019-0186-y pmid:31439937.
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi: 10.1136/bmj.m3544. PMID: 33106289.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma [correction in: J Hepatol 2019;70:817]. J Hepatol 2018;69:182-236. pmid:29628281.
Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci. 2019;20(6):1465. doi: 10.3390/ijms20061465. PMID: 30909504; PMCID: PMC6470895.
Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. doi:10.1155/2018/4756147 pmid:29974040.
O'Leary C, Mahler M, Soulen MC. Liver-directed therapy for hepatocellular carcinoma. Chin Clin Oncol. 2021;10(1):8. doi: 10.21037/cco-20-51. Epub 2020 May 30. PMID: 32527111.
Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: refining the current status based on emerging evidence and future perspectives. World J Gastroenterol 2018;24:5331-7. doi:10.3748/wjg.v24.i47.5331 pmid:30598578
Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol 2019;29:654-62. doi:10.1007/s00330-018-5617-6 pmid:30043160.
Vietti Violi N, Duran R, Guiu B, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol 2018;3:317-25. doi:10.1016/S2468-1253(18)30029-3 pmid:29503247.
Llovet JM, Real MI, Montaña X, et al., Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. doi:10.1016/S0140-6736(02)08649-X pmid:12049862.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22. doi:10.1016/S1470-2045(11)70175-9 pmid:22047762.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7. PMID: 26765068.
Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26(4):516-22. doi: 10.1016/j.jvir.2014.12.020. Epub 2015 Feb 18. PMID: 25704226.
Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. doi:10.1111/liv.12314 pmid:24251922.
Kudo M, Matsui O, Izumi N, et al., Liver Cancer Study Group of Japan. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology2014;87(Suppl 1):22-31. doi:10.1159/000368142 pmid:25427730.
Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:25-9. doi: 10.2147/JHC.S50359. PMID: 27574589; PMCID: PMC4994804.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. doi: 10.1056/NEJMoa0708857. PMID: 18650514.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. PMID: 19095497.
Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68(5):609-17. doi: 10.1111/ijcp.12352. Epub 2013 Nov 28. PMID: 24283303; PMCID: PMC4265239.
Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188391. doi: 10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10. PMID: 32659252.
Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959. doi: 10.1177/17562848211016959. PMID: 34104211; PMCID: PMC8165525.
Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs. 2020;80(12):1203-1210. doi: 10.1007/s40265-020-01361-5. PMID: 32671719; PMCID: PMC7395054.
Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs. 2020;80(3):315-322. doi: 10.1007/s40265-020-01263-6. PMID: 32034692.
Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18(12):1169-1175. doi: 10.1080/14737140.2018.1535315. Epub 2018 Oct 22. PMID: 30304963.
Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993-3036. PMID: 33042631; PMCID: PMC7539784.
May P, Normand C, Cassel JB, Del Fabbro E, Fine RL, Menz R, Morrison CA, Penrod JD, Robinson C, Morrison RS. Economics of Palliative Care for Hospitalized Adults With Serious Illness: A Meta-analysis. JAMA Intern Med. 2018;178(6):820-829. doi: 10.1001/jamainternmed.2018.0750. PMID: 29710177; PMCID: PMC6145747.
Publicado
2021-07-22
Cómo citar
Lizarzábal-García, M., & Mengual-Moreno, E. (2021). Modalidades de tratamiento locales y sistémicos de hepatocarcinoma: Local and systemic treatment modalities of hepatocarcinoma. Revista Profesional HígadoSano, (21), 36-45. https://doi.org/10.5281/zenodo.5120857
Número
Sección
Artículos
